Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Revolution Medicines Inc (Revolution Medicines) is a clinical-stage precision oncology company that develops novel targeted therapies for RAS-addicted cancers. The company’s pipeline products include RMC-6236 and RMC-9805 an investigational, oral, RAS(ON) multi-selective non-covalent inhibitor designed to treat pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC) and other solid tumors; RMC-6291 and RMC-5127 is an investigational, oral, RAS (ON) G12C and G12D selective covalent inhibitors that target solid tumors. It operates through its subsidiaries in the US and the UK. Revolution Medicines is headquartered in Redwood City, California, the US.
Headquarters
United States of America
Address
700 Saginaw Dr, Redwood City, California, 94063
Website
www.revmed.com
Telephone
1 650 4816801
No of Employees
883
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
RVMD (NASD)
EPS
XYZ
Net Income (2024)
XYZ
-88.5%
(2024 vs 2023)
Market Cap*
$43.3B
Net Profit Margin (2022)
XYZ
-436.1%
(2024 vs 2023)
* As of and is in US$
Revolution Medicines Inc premium industry data and analytics
Products and Services
| Products |
|---|
| Pipeline |
| Elironrasib RMC-6236: |
| Monotherapy: |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Contracts/Agreements | In August, the company collaborated with BeOne Medicines to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors. |
| 2026 | Regulatory Approval | In January, the company received a breakthrough designation from the U.S. Food and Drug Administration for zoldonrasib, a RAS(ON) G12D-selective inhibitor, for the treatment of adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC. |
| 2025 | Contracts/Agreements | In July, the company signed a partnership with Iambic Therapeutics to pursue novel drug candidates using Iambic’s leading AI models. |
Competitor Comparison
| Key Parameters | Revolution Medicines Inc | Eli Lilly and Co | Merck & Co Inc | Novartis AG | Bristol-Myers Squibb Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | Switzerland | United States of America |
| City | Redwood City | Indianapolis | Rahway | Basel | Princeton |
| State/Province | California | Indiana | New Jersey | Basel-Stadt | New Jersey |
| No. of Employees | 883 | 50,605 | 75,000 | 75,267 | 32,500 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Mark A. Goldsmith, M.D., Ph.D | Chairman; Chief Executive Officer; President | Executive Board | 2014 | 64 |
| Jack Anders | Chief Financial Officer | Senior Management | 2022 | 49 |
| Margaret Horn | Chief Operating Officer | Senior Management | 2018 | 63 |
| Wei Lin, M.D. | Chief Medical Officer | Senior Management | 2023 | - |
| Jan Smith, Ph.D. | Chief Scientific Officer | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer